Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068393 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00068393 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 39 participants.
The verdict
NCT00068393, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving doxorubicin together with gemcitabine works in treating patients with locally recurrent or metastatic unresectable renal cell carcinoma (kidney cancer).
Interventions
- DRUG Doxorubicin
- DRUG Gemcitabine
- DRUG Neulasta
- DRUG G-CSF (granulocyte-colony stimulating factor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-02-24 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068393
The ClinicalTrials.gov registry entry for NCT00068393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Doxorubicin is the first listed.
NCT00068393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068393 about?
NCT00068393 is a clinical study titled "Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma". RATIONALE: Drugs used in chemotherapy, such as doxorubicin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving doxorubicin together with ge...
What is the current status of trial NCT00068393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2004-02-24. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00068393?
The interventions under investigation include: Doxorubicin (DRUG), Gemcitabine (DRUG), Neulasta (DRUG), G-CSF (granulocyte-colony stimulating factor) (DRUG).
Who is sponsoring clinical trial NCT00068393?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.